The role of magnesium in migraine pathogenesis. Potential use of magnesium compounds in prevention and treatment of migraine headaches

• Autorzy: Rybicka M. , Baranowska-Bosiacka I. , Zyluk B. , Nowacki P. , Chlubek D.

Warianty tytułu

PL

Rola magnezu w patogenezie migreny. możliwości zastosowania związków magnezu w profilaktyce i leczeniu migrenowych bólów głowy

• Języki publikacji: EN

Abstrakty

EN

One of the major functions of magnesium is the maintenance of proper electric potential of neurons. Pathological conditions associated with systemic magnesium deficiencies may be associated with disturbance of numerous neurophysiological processes. These may include neuron function, transmission of nerve impulses, neuromuscular transmission, muscle contraction and vasomotor reflex. Therefore, magnesium deficiencies, particularly those associated with hypomagnesemia, are a source of problems for neurologists. Migraine is one of the most common neurological disorders. Despite many years of research, pathophysiology of migraine has not been elucidated. The predominant opinion is that the onset of migraine headaches is associated with cerebral vascular spasms. Based on the available knowledge of biological functions of magnesium, at least several feasible mechanisms for prevention or reduction of the intensity of migraine attacks by magnesium ions have been proposed. The goal of this review is to summarize the literature reports on magnesium in the pathogenesis of migraine and to identify the potential uses for magnesium compounds in prevention and treatment of migraine headaches.

PL

Jedną z najważniejszych funkcji magnezu jest utrzymywanie odpowiedniego potencjału elektrycznego komórek nerwowych. W stanach patologii związanych z ogólnoustrojowymi niedoborami magnezu może dochodzić do zakłócenia rozmaitych procesów neurofizjologicznych. Należą do nich m.in.: funkcjonowanie neuronów, przewodzenie impulsu nerwowego, przekaźnictwo nerwowo-mięśniowe i skurcz mięśni oraz odruch wazomotoryczny. Z powyższych względów stany niedoborów magnezu, zwłaszcza te przebiegające z hipomagnezemi ą, stały się problemem w praktyce klinicznej lekarza neurologa. Migrena jest jednym z najczęściej występujących schorzeń neurologicznych. Pomimo wielu lat badań, jej patofizjologia nie została jednoznacznie wyjaśniona. Aktualnie dominuje pogląd, iż pojawianie się migrenowych bólów głowy ma związek ze skurczem naczyń mózgowych. Na podstawie dostępnej wiedzy dotyczącej biologicznych funkcji magnezu zasugerowano istnienie przynajmniej kilku możliwych mechanizmów, za których pośrednictwem jony magnezu mogłyby zapobiegać pojawianiu się ataków migreny lub ograniczać ich nasilenie. Celem pracy było podsumowanie dostępnych w piśmiennictwie doniesień dotyczących roli magnezu w patogenezie migreny, a także wskazanie możliwości wykorzystania preparatów magnezu w profilaktyce i leczeniu migrenowych bólów głowy.

• Wydawca: -
• Czasopismo: Journal of Elementology
• Rocznik: 2012
• Tom: 17
• Numer: 2
• Opis fizyczny: p.345-356,ref.

Twórcy

autor

Rybicka M.

• Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin

autor

Baranowska-Bosiacka I.

autor

Zyluk B.

autor

Nowacki P.

autor

Chlubek D.

Bibliografia

• Abu-Arefeh I., Razak S., Sivaraman B., Graham C. 2010. Dev. Med. Child. Neurol., 2010. 52(12): 1088-1097. DOI: 10.1111/j. 1469-8749.2010.03793.x.
• Allais G., Bussone G., De Lorenzo C., Mana O., Benedetto C. 2005. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol. Sci., 26(suppl.2): s125-s129, DOI: 10.1007/s10072-005-0424-7
• Altura B.M. 1985. Calcium antagonism properties of magnesium: Implications for antimigraine actions. Magnesium, 4(4): 169-175.
• Antonaci F. 2010. A review of current European treatment guidelines for migraine. J. Headache Pain, 11(1): 13-19. DOI: 10.1007/s10194-009-0179-2
• Bigal M.E., Bordini C.A., Sheftell F.D., Speciali J.G., Bigal J.O. 2002. Migraine with aura versus migraine without aura: pain intensity and associated symptom intensities after placebo. Headache, 42(9): 872-877. DOI: 10.1046/j.1526-4610.2002.02205.x
• Bo S., Pisu E. 2008. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr. Opin. Lipidol. 19(1): 50-56. DOI: 10.1097/ /MOL.0b013e3282f33ccc
• Buse D.C., Rupnow M.F.T., Lipton R.B. 2009. Assessing and managing all aspects of migraine: migraine attacks, migraine related functional impairment, common comorbidities, and Quality of Life. Mayo Clin. Proc., 84(5): 422-435. DOI: 10.4065/?84.5.422
• Cete Y., Dora B., Ertan C., Ozdemir C., Oktay C. 2005. A randomized prospective placebocontrolled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia, 25(3): 199-204. DOI: 10.1111/j.1468-2982.2004.00840.x
• Corbo J., Esses D., Innacome R., Bijur P., Gallagher E.J. 2000. Randomized clinical trial of intravenous magnesium sulfate as adjunctive medication for ED treatment of migraine headache. J. Emerg. Med, 38(6): 621-627. DOI: 10.1111/j.1468-2982.2004.00840.x
• D’Amico D., Tepper S.J. 2008. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr. Dis. Treat., 4(6): 1155-1167.
• De Feo M.L. 2009. Magnesium disorders: clinical experience and review of the literature. Clin. Cases Miner. Bone. Metab., 6(3): 220-222.
• DeMaagd G. 2008. The pharmalogical management of migraine. Part 2. P. T., 33(8): 480-487.
• Demirkaya S., Dora B., Topcuoaglu M.A., Ulas U.H., Vural O. 2000. A comparative study of magnesium, flunarizine and amitriptiline in the prophylaxis of migraine. J. Headache Pain, 1(3): 179-186. DOI: 10.1007/s101940070041
• Demirkaya S., Vural O., Dora B., Topçuodlu M.A. 2001. Efficacy of intravenous magnesium sulphate in the treatment of acute migraine attacks. Headache, 41(2): 171-177. DOI: 10.1046/j.1526-4610.2001.111006171.x
• Diamond S., Bigal M.E., Silberstein S. 2007. Patterns of diagnosis and acute and preventive Treatment for Migraine in the United States: Results from the American migraine prevalence and prevention study. Headache, 47(3): 355-363. DOI: 10.1111/j.1526-4610.2006.00631.x
• Dib M. 2008. Optimizing prophylactic treatment of migraine: Subtypes and patient matching. Ther. Clin. Risk. Manag., 4(5): 1061-1078. DOI: http://dx.doi.org/10.2147/ TCRM.S3983
• Dribben W.H., Eisenman L.N., Mennerick S. 2010. Magnesium induces neuronal apoptosis by suppressing excitability. Cell Death Dis., 1(8): e63 DOI:10.1038/cddis.2010.39
• Dullo P., Vedi N. 2008. Changes in serum calcium, magnesium and inorganic phosphorus levels during different phases of menstrual cycle. J. Hum. Reprod. Sci., 1(2): 77-80.
• Durlach J. 1976. Neurological manifestations of magnesium imbalance. In: Handbook of clinical neurology. Vinken P.J., Bruyn G.W. (eds.) vol.28.
• Evans R.W., Taylor F.R. 2006. Natural or alternative medications for migraine prevention. Headache, 46(6): 1012-1018. DOI: 10.1111/j.1526-4610.2006.00473.x
• Facchinetti F., Sances G., Borella P., Genazzani A.R., Nappi G. 1991. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache, 31(5): 298-301. DOI: 10.1111/j.1526-4610.1991.hed3105298.x
• Gallai V., Sarchielli P., Goata G., Firenze C., Morucci P., Abbritti G. 1992. Serum and salivary magnesium levels in migraine. Results in a group of juvenile patients. Headache, 32(3): 132-135. DOI: 10.1111/j.1526-4610.1992.hed3203132.x
• Ginder S., Oatman B., Pollack M. 2000. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. J. Emerg. Med., 18(3): 311-315. D0I:10.1016/S0736-4679(99)00220-6
• Goadsby P.J., Lipton R.B., Ferrari M.D. 2005. Migraine current understanding and treatment. N. Engl. J. Med., 346(4): 257-270.
• Grubb B.P., Carmo Jorge S. 2000. A review of the classification, diagnosis, and management of autonomic dysfunction syndromes associated with orthostatic intolerance. Arq. Bras. Cardiol., 74(6): 545-552. dx.doi.org/10.1590/S0066-782X2000000600008
• Grubb B.P. 2005. Neurocardiogenic syncope and related disorders of orthostatic intolerance. Circulation. 111: 2997-3006. D0I:10.1161/CIRCULATI0NAHA.104.482018
• Hu X.H., Markson L.E., Lipton R.B., Stewart W.F., Berger M.L. 1999. Burden of migraine in the United States. Arch. Intern. Med., 159(8): 813-818.
• Hu L., Yang H., Shi J., Cui J. 2006. Effects of multiple metal binding siteson calcium and magnesium-dependent activation of BK channels. J. Gen. Physiol. 127(1): 35-50. DOI: 10.1085/jgp.200509317
• Koseoglu E., Talashoglu A., Gonul A.S., Kula M. 2008. The effect of magnesium prophylaxis in migraine without aura. Magnes. Res, 21(2): 101-108. DOI: 10.1684/mrh.2008.0132 101
• Kurth T. 2007. Migraine and ischaemic vascular events. Cephalalgia, 27(8): 965-75. Erratum in: Cephalalgia., 27(11): 1290. DOI: 10.1111/j.1468-2982.2007.01405.x
• Kurth T., Schürks M., Logroscino G., Buring J.E. 2009. Migraine frequency and risk of cardiovascular disease in women. Neurology, 73(8): 581-588. DOI: 10.1212/WNL. 0b013 e3181ab2c20
• Lauritzen M. 2001. Cortical spreading depression in migraine. Cephalalgia, 21(7): 757-760. DOI: 10.1111/j.1468-2982.2001.00244.x
• Lipton R.B., Liberman J.N., Kolodner K.B., Bigal M.E., Dowson A., Stewart W.F. 2003. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia, 23(6): 441-450. DOI: 10.1046/j.1468- 2982.2003.00546.x
• Mauskop A. 2001. Alternative therapies in headache: is there a role? Med. Clin. North. Afr., 85(4): 1077-1081. D0I:10.1016/S0025-7125(05)70360-6
• Mauskop A., Altura B.T., Altura B.M. 2002. Serum ionized magnesium levels and serum ionized calcium /ionized magnesium ratios in women with menstrual migraine. Headache, 42(4): 244-248. DOI: 10.1046/j.1526-4610.2002.02075.x
• Mauskop A., Altura B.T., Cracco R.Q., Altura B.M. 1995. Intravenous magnesium sulfate relieves cluster headaches in patients with low serum ionized magnesium levels. Headache, 35(10): 597-600. DOI: 10.1111/j.1526-4610.1995.hed3510597.x
• Mauskop A., Altura B.T., Cracco R.Q., Altura B.M. 1995. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin. Sci. (Colch.), 89(6): 633-636.
• McKee J.A., Brewer R.P., Macy G.E., Philips-Bute B., Campbell K.A., Borel C.O., Reynolds J.D., Warner D.S. 2005. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: A study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit. Care Med. 33(3): 661-666. D0I:10.1097/ /01.CCM.0000156293.35868.B2
• Mishima K., Takeshima T., Shimomura T., Okada H., Kitano A., Takahasi K., Nakashima K. 1997. Platelet ionized magnesium, cyclic AMP and cyclic GMP levels in migraine and tension-type headache. Headache, 37(9): 561-564. DOI: 10.1046/j.1526-4610.1997.3709561.x
• Moodi S., Lowder D.M. 2006. Medication for migraine prophylaxis. Am. Fam. Physician. 73(1): 72-78.
• Olesen J., Steiner T.J. 2004. The international classification of headache disorders, 2nd edition (ICHD-II). J. Neurol. Neurosurg. Psychiatry, 75(6): 808-811 DOI: 10.1136/ /jnnp.2003.031286
• Peikert A., Wilimzig C., Köhne-Volland R. 1996. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study., 16(4): 257-63. DOI: 10.1046/j.1468-2982.1996.1604257.x
• Pfaffenrath V., Wessely P., Meyer C., Isler H.R., Evers S., Grotemeyer K.H., Taneri Z., Soyka D., Göbel H., Fischer M. 1996. Magnesium in the prophylaxis of migraine-a double-blind, placebo-controlled study. Headache, 16(6): 436-440. DOI: 10.1046/j. 1468-2982.1996.1606436.x
• Pringsheim T., Davenport J.W., Becker W.J. 2010. Prophylaxis of migraine headache. CMAJ., 182(7): E269-E276. DOI: 10.1503/cmaj.081657.
• Ramadan N.M., Halvorson H., Vande-Linde A., Levine S. R., Helpern J.A., Welch K.M.A. 1989. Low brain Magnesium in migraine. Headache, 29(7): 416-419. DOI: 10.1111/j.1526- 4610.1989.hed2907416.x
• Romani A.M. 2008. Magnesium homeostasis and alcohol consumption. Magnes. Res., 21(4): 197-204. DOI: 10.1684/mrh.2008.0152
• Safavi M., Honarmand A. 2007. Admission hypomagnesemia — impact on mortality or morbidity in critically ill patients. Middle East J.Anesthesiol. 19(3): 645-660.
• Schrucks M., Buring J.E., Kurth T. 2010. Migraine, migraine features, and cardiovascular disease. Headache, 50(6): 1031-1041. DOI: 10.1111/j.1526-4610.2009.01609.x
• Shuen A.Y., Wong B.Y.L., Wei C., Liu Z., Li M., Cole D.E.C. 2009. Genetic determinants of extracellular magnesium concentration: Analysis of multiple candidate genes, and evidence for association with the estrogen receptor a (ESR1) locus.): 28-32.
• Silberstein S.D. 2000. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the quality standards Subcommittee of the American Academy of Neurology. Neurology, 55(6): 754-762.
• Silberstein S.D., Goldberg J. 2007. Menstrually related migraine breaking the cycle in your clinical practice. J. Reprod. Med.; 52(10): 888-895.
• Smeets M.C., Vernoy C.B., Souverijn J.H.M., Ferrari M.D. 1994. Intracellular and plasma magnesium in familial hemiphlegic migraine and migraine with and without aura. Cephalalgia, 14(1): 29-32. DOI: 10.1046/j.1468-2982.1994.1401029.x
• Sontia B., Touyz R. 2007. Role of magnesium of hypertension. Arch. Biochem. Biophys., 458(1): 33-9.
• Stang P, Cady R.K., Batenhorst A.S., Hoffman L. 2001. Workplace productivity: a review of the impact of migraine and its treatment. Pharmacoeconomics., 19(3): 231-244.
• Sun-Edelstein C., Mauskop A. 2011. Alternative headache treatments: Nutraceuticals, behavioral and physical treatments. Headache., 5(3): 469-483. DOI: 10.1111/j.1526- 4610.2011.01846.x
• Sun-Edelstein C., Mauskop A. 2009. The role of magnesium in the pathogenesis and treatment of migraine. Expert Rev. Neurother. 9(3): 369-379.
• Taylor F. 2011. Nutraceuticals and Headache: The biological basis. Headache, 51(3): 484-501. DOI: 10.1111/j.1526-4610.2011.01847.x
• Tietjen E.G. 2007. Migraine and ischaemic heart disease and stroke: potential mechanisms and treatment implications. Cephalalgia, 27(8): 981-987.
• Wang F., Van Den Eeden S.K., Ackerson M.L., Salk S.E., Reince R.H., Elin R.J. 2003. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: A randomized, double-blind, placebo-controlled Trial. Headache, 43(6): 601-610. DOI: 10.1046/ /j.1526-4610.2003.03102.x
• Weinberger J. 2006. Interactions between migraine and stroke. Curr. Treat. Option. Neurol. 8(6): 513-517. DOI: 10.1007/s11940-006-0041-7
• Whang R., Ryder K.W. 1990. Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine. JAMA, 263(22): 3063-4. D0I:10.1001/jama.1990.03440220087036
• Wolf F.I., Trapani V., Cittadini A. 2008. Magnesium and the control of cell proliferation: looking for a needle in a haystack. Review. Magnes. Res., 21(2): 83-91. DOI: 10.1684/ mrh.2008.0138
• Zidverc-Trajkovi J., Pavlovi A.M., Jovanovi Z., Šternic N., Kostić V.S. 2001. Efficacy of intravenous magnesium sulfate in severe migraine attacks. J. Headache Pain, 2(2): 79-82. DOI: 10.1007/PL00012190

Uwagi

PL

Rekord w opracowaniu